ArticleExperimental and therapeutic medicine2014
MicroRNA-203 inhibits malignant melanoma cell migration by targeting versican.
Article in Experimental and therapeutic medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.Frontiers in oncology · 2021Review
- A multi-omics study on cutaneous and uveal melanoma.International journal of ophthalmology · 2021Article
- Distinguishing Tumor and Stromal Sources of MicroRNAs Linked to Metastasis in Cutaneous Melanoma.Translational oncology · 2020Article
- A novel chalcone derivative has antitumor activity in melanoma by inducing DNA damage through the upregulation of ROS products.Cancer cell international · 2020Article
- Importance of microRNAs in Skin Oncogenesis and Their Suitability as Agents and Targets for Topical Therapy.Skin pharmacology and physiology · 2020Review
- Targeting of stromal versican by miR-144/199 inhibits multiple myeloma by downregulating FAK/STAT3 signalling.RNA biology · 2020Article
- Clinical significance of circulatory microRNA-203 in serum as novel potential diagnostic marker for multiple myeloma.Journal of cancer research and clinical oncology · 2019Article
- MicroRNA Dysregulation in Cutaneous Squamous Cell Carcinoma.International journal of molecular sciences · 2019Review
- Epigenetic inactivation of miR-203 as a key step in neural crest epithelial-to-mesenchymal transition.Development (Cambridge, England) · 2019Article
- Glucocorticoids Improve Myogenic Differentiation In Vitro by Suppressing the Synthesis of Versican, a Transitional Matrix Protein Overexpressed in Dystrophic Skeletal Muscles.International journal of molecular sciences · 2017Article
- miR-124 inhibits proliferation, migration and invasion of malignant melanoma cells via targeting versican.Experimental and therapeutic medicine · 2017Article
- RAB22A overexpression promotes the tumor growth of melanoma.Oncotarget · 2016Article
- Pivotal MicroRNAs in Melanoma: A Mini-Review.Molecular diagnosis & therapy · 2016Review
- Decreased expression of hyaluronan synthase 1 and 2 associates with poor prognosis in cutaneous melanoma.BMC cancer · 2016Article
- Inhibition of versican expression by siRNA facilitates tropoelastin synthesis and elastic fiber formation by human SK-LMS-1 leiomyosarcoma smooth muscle cells in vitro and in vivo.Matrix biology : journal of the International Society for Matrix Biology · 2016Article
- MicroRNA-9 suppresses the growth, migration, and invasion of malignant melanoma cells via targeting NRP1.OncoTargets and therapy · 2016Article
- miR-203 Inhibits Frizzled-2 Expression via CD82/KAI1 Expression in Human Lung Carcinoma Cells.PloS one · 2015Article
- A role for versican in the development of leiomyosarcoma.The Journal of biological chemistry · 2014Article
Corrections and comments
- Retraction · 2023-11-20Author Unresponsive · Concerns/Issues about Image · Euphemisms for Plagiarism · Investigation by Journal/Publisher · Investigation by Third Party · Paper Mill · Plagiarism of Image · · see also: https://pubpeer.com/publications/E90686ECA59A1A587DF89128D30C75
- Retracted
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNA (miR)-203 has been demonstrated to function as a suppressor in tumorigenesis. Recently, miR-203 was reported to play a role in malignant melanoma (MM); however, the detailed function of miR-203 in MM remains unclear. In the present study, the expression of miR-203 was shown to be significantly downregulated in MM tissues when compared with normal adjacent tissues. Based on a bioinformatic prediction, versican was further identified as a novel target of miR-203, and the expression of versican was markedly increased in MM tissues. Inhibition of miR-203 increased the protein expression of versican, while upregulation of miR-203 inhibited the protein expression of versican in MM A375 cells. In addition, the upregulation of versican significantly promoted A375 cell migration; however, upregulation of miR-203 suppressed A375 cell migration. The present study further investigated whether miR-203 was involved in versican-mediated A375 cell migration, and the results indicated that upregulation of miR-203 significantly inhibited A375 cell migration, which was impaired by overexpression of versican. These observations indicated that versican functions as a downstream effector in miR-203-mediated MM cell migration. Therefore, the results demonstrated that miR-203 exhibited an inhibitory effect on MM cell migration via directly targeting versican, thus, may become an effective inhibitor for MM metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.